Key Insights

Highlights

Success Rate

78% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

10.0%

2 terminated out of 20 trials

Success Rate

77.8%

-8.7% vs benchmark

Late-Stage Pipeline

20%

4 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed with results

Key Signals

1 with results78% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (6)
P 1 (1)
P 2 (3)
P 3 (3)
P 4 (1)

Trial Status

Completed7
Unknown4
Recruiting4
Terminated2
Active Not Recruiting2
Not Yet Recruiting1

Trial Success Rate

77.8%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT07105670Not ApplicableRecruitingPrimary

Effects of Replacing High Protein Foods in People With Chronic Kidney Disease

NCT05884866Phase 2Completed

A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.

NCT06939816Phase 2Terminated

Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)

NCT06721143Phase 1RecruitingPrimary

A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)

NCT06925217Not ApplicableRecruiting

Closed-Loop Impact on Chronic Kidney Disease in Type 2 Diabetes

NCT07260292Not ApplicableCompletedPrimary

KPs Supplement for Inflammation, Oxidative Stress and Lipid Abnormalities in CKD Patients.

NCT05797506Phase 2Active Not RecruitingPrimary

Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease

NCT06732349RecruitingPrimary

Urinary Tubular Biomarkers for Chronic Kidney Disease

NCT06956872Not ApplicableNot Yet RecruitingPrimary

Clinical Effectiveness of MyNutriKidney®

NCT05169411Completed

Preserving Kidney Function in Children With Chronic Kidney Disease

NCT05198284Active Not Recruiting

Prospective Decision Impact Clinical Utility Trial of KidneyIntelX

NCT05225454Unknown

The Life Style Patterns and the Development Trend of Chronic Diseases in Healthy and Sub-healthy Groups Were Analyzed by Using Data-mining Techniques

NCT03529071Not ApplicableTerminatedPrimary

Empowering Veterans to Communicate With Healthcare Providers

NCT04012957Phase 3CompletedPrimary

Desidustat in the Treatment of Anemia in CKD

NCT04172103Completed

The Association Between the Duration of Acute Kidney Injury and New-onset Chronic Kidney Disease After Cardiac or Thoracic Aortic Surgery

NCT03242252Phase 3Completed

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control

NCT03311321Not ApplicableUnknown

Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients

NCT01509716UnknownPrimary

Assessing Perceived Versus Actual Knowledge and Quality of Life in Pre-Dialysis Chronic Kidney Disease (CKD) Patients

NCT01748396Phase 4CompletedPrimary

Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol

NCT01709994Phase 3Unknown

Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients

Showing all 20 trials

Research Network

Activity Timeline